Abstract Details

Title Comparison of DRD2, DRD3 and NMDA Receptor Genotype Polymorphisms in Parkinson's Patients and Controls

Topic Movement Disorders

Presentation(s) P05 - (-)

Poster/Presentation
Number 053

Objective

Background BACKGROUND: Impulse control disorders (ICDs) in Parkinson disease are associated with DRD3, DRD2 and NMDA receptor genotype polymorphisms. However it is unknown whether these genotype receptor polymorphisms are associated with susceptibility to PD.

Design/Methods DESIGN/METHODS: Genotype polymorphism analysis for rs1800497 (DRD2), rs6280 (DRD3), and rs7301328 (NMDA GRIN 2B) was performed on stored blood of 664 PD patients and 718 normal controls. Demographic and clinical data was recorded. There was no departure from Hardy-Weinberg equilibrium in study controls (P>0.05). Single-SNP associations with PD were evaluated using logistic regression models adjusted for age and gender. Additive, dominant and recessive models were utilized.

Results RESULTS: There was evidence of an association between rs1800497 and PD under an additive model (OR:1.31, P=0.0065), and a dominant model (OR: 1.36, P=0.0096) with a non-significant trend towards association under a recessive model (OR:1.54, P=0.12). There was an association between rs7301328 and PD under a dominant model (OR: 1.26, P=0.048) but not under an additive model (OR: 1.11, P=0.20) or recessive model (OR: 0.97, P=0.86). There was no evidence of an association with PD for rs6280 under any statistical model (all P?0.73).

Conclusions CONCLUSIONS: DRD2 (rs1800497) and NMDA GRIN 2B (rs7301328) receptor polymorphisms may contribute to the risk of PD, but not DRD3 (rs6280). Extending our study to compare patients with and without ICDs in the PD cohort is warranted to further define the relationship.

Authors/Disclosures
Anhar Hassan, MBBCH, FRACP, FRCPI, FAAN (Beaumont Hospital) PRESENTER	The institution of Dr. Hassan has received research support from Intrabio . Dr. Hassan has received personal compensation in the range of $500-$4,999 for serving as a Invited speaker with Korean Movement Disorders Society.
Michael S. Okun, MD, FAAN (University of Florida)	Dr. Okun has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Okun has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Parkinson's Foundation. Dr. Okun has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Neurology. Dr. Okun has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Journal Watch. The institution of Dr. Okun has received research support from NIH. The institution of Dr. Okun has received research support from Parkinson's Foundation. The institution of Dr. Okun has received research support from Tourette Association of America. The institution of Dr. Okun has received research support from Michael J Fox. Dr. Okun has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
Daniel Weintraub	Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
J. E. Ahlskog, MD, PhD (Mayo Clinic)	Dr. Ahlskog has received publishing royalties from a publication relating to health care.
Owen A. Ross, PhD (Mayo Clinic Jacksonville)	Dr. Ross has nothing to disclose.

��ɫ��

��ɫ��